Skip to content

Comparison of efficacy of 5-FU cream and methotrexate gel in acral vitiligo lesions

A split-body study to compare the efficacy of combination of CO2 laser and topical methotrexate 1% versus CO2 laser and 5-fluorouracil 5% in stable acral vitiligo. - Nil

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/055546
Enrollment
30
Registered
2023-07-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Methotrexate 1% gel: Topical methotrexate 1% gel once daily will be applied over the patches of vitiligo after Fractional CO2 Laser. Control Intervention1: 5-fluorouracil 5% cream: 5-fl

Sponsors

All India Institute of Medical Sciences Bhubaneswar Odisha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age >18 years 2. Patients with stable acral or acrofacial vitiligo and nonsegmental vitiligo having bilateral symmetrical lesions. 3. Two independent areas of size at least 1 x 1 cm or a single lesion with minimal size of at least 2 x 2 cm. 4. Patients who have not undergone any surgical management for the vitiligo.

Exclusion criteria

Exclusion criteria: 1. Patients with active vitiligo with signs of active vitiligo like confetti- like depigmentation, new lesions in the surrounding area, or the extension of existing lesions in the last 12 weeks. 2. History of keloidal tendency/hypertrophic or keloidal scarring 3. Collagen vascular disease and bleeding disorders 4. Any active bacterial, fungal or viral infection over the lesional site 5. Pregnant and lactating females 6. Age less than 18 years 7. Patients on anticoagulant therapy or aspirin 8. Patients with an unrealistic expectation

Design outcomes

Primary

MeasureTime frame
Proportion of patients achieving 50% reduction in lesional vitiligo area & severity index (VASI) from baseline at five months.Timepoint: 5 months

Secondary

MeasureTime frame
â?¢ Time to achieve a 50% reduction in lesional VASI from baseline. â?¢ Proportion of patients achieving 75% reduction in lesional VASI from baseline at five months. â?¢ Time to achieve a 75% reduction in VASI from baseline. â?¢ Patient satisfaction using Patientsâ?? global assessment score. â?¢ Adverse events, if any.Timepoint: 5 months

Countries

India

Contacts

Public ContactVishal Thakur

All India Institute of Medical Sciences, Bhubaneswar

drvishal87igmc@gmail.com9878576002

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026